Our clinical experiences in patients with de novo and secondary metastatic breast cancers
Küçük Resim Yok
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Bayrakol Medical Publisher
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Aim: While breast cancer may be de novo, that is, metastatic at the time of diagnosis, a local tumor at initial diagnosis may metastasize to other regions over the course of treatment and follow-up. This study aimed to reveal the clinical, pathological, and survival differences in patients with de novo metastatic and secondary metastatic breast cancer who were followed up and treated in our clinic, and to investigate factors that may have an effect on survival.Material and Methods: The data of female patients who were diagnosed with metastatic breast cancer, treated, and followed up in our clinic between January 2000 and May 2021 were retrospectively analyzed. Patients were divided into two groups: the de novo metastatic disease group (Group 1) and the secondary metastatic disease group (Group 2). Clinical and pathological data of the groups were analyzed.Results: Patients with de novo metastatic disease most commonly had bone metastases. But in the secondary metastatic disease group, the most common metastasis type was multiorgan metastases. The rate of triple negativity was significantly lower in Group 1. When the groups were analyzed in terms of survival, the median time was 77 +/- 10.89 months in the de novo metastatic group and 66 +/- 10.15 months in the secondary metastatic group (p=0.05).Discussion: Our study demonstrated that de novo metastatic breast cancers had a better prognosis than secondary metastatic breast cancers even though they tend to metastasize early.
Açıklama
Anahtar Kelimeler
Breast Cancer, De Nov, Metastasis Survival
Kaynak
Annals Of Clinical And Analytical Medicine
WoS Q Değeri
Scopus Q Değeri
Cilt
14
Sayı
4
